Last Monday, the U.S. Food and Drug Administration (FDA) approved the Alzheimer's drug aducanumab, using its "accelerated approval" program. Prof. Dr. Mathias Jucker talks about the drug with the Hertie Foundation (interview in German only).
Prof. Dr. Mathias Jucker